Summary
Common Side Effects
Important Context: All side effect data below come from Phase 3 REDEFINE trials of CagriSema. These rates are higher than semaglutide alone due to the additive effects of cagrilintide (amylin analog). Most events were mild to moderate and resolved over time.
Most Common Adverse Events (REDEFINE 1)
| Adverse Event | CagriSema | Placebo | Difference |
|---|---|---|---|
| Nausea | 55.0% | 12.6% | +42.4 pp |
| Constipation | 30.7% | 11.6% | +19.1 pp |
| Vomiting | 26.1% | 4.1% | +22.0 pp |
| Diarrhea | Reported | Lower | Similar to semaglutide |
| Abdominal Pain | Reported | Lower | Part of GI cluster |
| Overall GI Events | 79.6% | 39.9% | +39.7 pp |
Discontinuation Due to Adverse Events
Individual Side Effect Details
Nausea
Constipation
Vomiting
Diarrhea
Abdominal Pain
Dual Mechanism = Additive GI Effects
How CagriSema Works
CagriSema combines cagrilintide (amylin analog) with semaglutide (GLP-1 agonist). Both components slow gastric emptying and affect GI function, creating additive side effects—but also synergistic weight loss (22.7% vs 16.1% for semaglutide alone).
Why GI Side Effects Are Higher Than Semaglutide Alone
What it does: Amylin is a hormone co-secreted with insulin that slows gastric emptying, suppresses glucagon, and promotes satiety. Cagrilintide mimics amylin at longer duration.
Side effect connection: Amylin's gastric-slowing effects add to semaglutide's already significant delay in stomach emptying. This "double delay" increases nausea, vomiting, and fullness.
Evidence: Vomiting is 9.57x more common with CagriSema vs semaglutide alone, suggesting the amylin component substantially amplifies this specific side effect.[2]
What it does: GLP-1 receptor agonists slow gastric emptying, activate satiety centers in the brain, and reduce appetite. Semaglutide is the same drug in Wegovy/Ozempic.
Side effect connection: GLP-1 activation causes nausea, constipation, and diarrhea through slowed gut motility and receptor activation in nausea centers.
Why combination matters: Semaglutide alone causes GI effects in 40-60% of users. Adding cagrilintide increases this to 79.6%, demonstrating additive (not just overlapping) mechanisms.
What happens: Both amylin and GLP-1 slow how quickly food leaves your stomach, but through different pathways (amylin via area postrema; GLP-1 via vagal afferents).
Side effect connection: The combined effect creates more pronounced fullness, bloating, nausea, and constipation than either drug alone. Food literally stays in your stomach longer than with single-agent therapy.
Trade-off: This intense gastric slowing is precisely why CagriSema produces superior weight loss (22.7% vs 16.1% for semaglutide alone)—you feel fuller longer and eat less.[1]
Despite 79.6% experiencing GI side effects, only 6% discontinued treatment. Why?
- Transient nature: Most GI symptoms peak early and improve over 4-8 weeks as your body adapts
- Mild-to-moderate severity: The majority of events were not severe enough to require stopping medication
- Superior efficacy: 22.7% weight loss is among the highest ever reported—many patients tolerate side effects for these results
- Weekly dosing: Once-weekly injections allow recovery time between doses
Class Effect Context: CagriSema's GI side effects are consistent with both the GLP-1 agonist class (nausea, diarrhea) and amylin analogs (vomiting, delayed gastric emptying). The combination amplifies these effects but does not introduce new safety signals beyond what's expected from each component.[1]
Dose Escalation & Management Strategies
CagriSema uses a gradual dose escalation protocol in REDEFINE trials to improve tolerability. The combination is dosed as a fixed-dose product containing both cagrilintide 2.4 mg and semaglutide 2.4 mg.
- Week 0-4: Lower starting dose (specific titration schedule TBD at FDA approval)
- Week 4-8: Gradual increase to intermediate dose
- Week 8-12: Continue escalation
- Week 12+: Maintenance dose of cagrilintide 2.4 mg + semaglutide 2.4 mg
Comparison: CagriSema vs Semaglutide Alone
| Measure | CagriSema | Semaglutide Alone | Difference |
|---|---|---|---|
| Weight Loss | 22.7% | 16.1% | +6.6 pp (41% greater) |
| Nausea Rate | 55% | ~40-50% | Similar |
| Vomiting Rate | 26.1% | ~5-10% | 9x higher (OR 9.57) |
| Overall GI Events | 79.6% | ~50-60% | 2.9x higher (OR 2.91) |
| Discontinuation | 6.0% | ~5-7% | Similar |
Trade-off Analysis: CagriSema delivers 41% greater weight loss (22.7% vs 16.1%) at the cost of higher vomiting rates (26% vs ~5-10%) and overall GI events (80% vs ~50-60%). However, discontinuation rates remain similar, suggesting the added efficacy is worth the tolerability trade-off for most patients.
Sources
- Novo Nordisk. "CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in NEJM." PR Newswire. June 22, 2025. Link
- "Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis." PMC. 2024. Link
- "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2025. doi:10.1056/NEJMoa2502081. Link
- "Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes." N Engl J Med. 2025. doi:10.1056/NEJMoa2502082. Link
- Frias JP, et al. "Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial." Lancet. 2023. PMID: 37364590. Link
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.